FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017380046> ?p ?o ?g. }

• W3017380046 abstract "Abstract Background Biomarkers can play a critical role by facilitating diagnosis and stratification of disease, as well as assessment or prediction of disease severity. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 product ([TIMP-2] × [IGFBP7]) predict the development and progression of AKI and recently procalcitonin (PCT), a widely used biomarker for sepsis diagnosis and management, has been associated with AKI occurrence in ICU patients. To assess combinations of [TIMP-2] × [IGFBP7] and PCT results for prediction and risk stratification of short-term outcomes in septic and non-septic patients, a retrospective cohort analysis of critically ill patients was performed in a multidisciplinary ICU. ROC curve analysis was used in order to evaluate predictive performance of combined results of [TIMP-2] × [IGFBP7] and PCT at the time of admission for AKI development. To verify the utility of adding [TIMP-2] × [IGFBP7] and PCT results for risk assessment, we evaluated the predictive value of having a single-marker positivity compared to a double-marker positivity using the widely used cut-off of 0.3 (ng/mL) 2 /1000 for [TIMP-2] × [IGFBP7] and 0.5 μg/L for PCT. Risk assessment for AKI occurrence within 48 h, acute kidney disease (AKD) and mortality at 7 days was performed by logistic/Cox regression analysis. Results 433 patients were analysed, of whom 168 had AKI within 48 h (93 septic and 65 non-septic patients). Combination of [TIMP-2] × [IGFBP7] and PCT showed a good predictive ability for AKI occurrence (AUC 0.81, 95% CI 0.77–0.86, p < 0.001, Sens 78%, Spec 73%). Combinations of biomarkers increased the odd ratios (OR) considerably. A single-marker positivity showed a fourfold risk increase, while the double-marker positivity a 26-fold risk increase for AKI occurrence. Moreover, the double-marker positivity showed an elevated risk for AKD at 7 days in non-septic patients (OR 15.9, 95% CI 3,21–73,57, p < 0.001) and for mortality within 7 days in septic patients (HR 4.1, 95% CI 1.4–11.8, p = 0.001). Conclusions Although combining the results of [TIMP-2] × [IGFBP7] and PCT may be a useful tool to identify and stratify ICU patients at high risk for septic AKI and short-term adverse outcomes, data should be confirmed in a large prospective study." @default.
• W3017380046 created "2020-04-24" @default.
• W3017380046 creator A5024171732 @default.
• W3017380046 creator A5040344241 @default.
• W3017380046 creator A5044009212 @default.
• W3017380046 creator A5044324138 @default.
• W3017380046 creator A5049227846 @default.
• W3017380046 creator A5049470840 @default.
• W3017380046 creator A5050853495 @default.
• W3017380046 creator A5053612775 @default.
• W3017380046 creator A5061657411 @default.
• W3017380046 creator A5066223278 @default.
• W3017380046 creator A5069947952 @default.
• W3017380046 creator A5076403607 @default.
• W3017380046 creator A5082770243 @default.
• W3017380046 creator A5088519816 @default.
• W3017380046 creator A5088632570 @default.
• W3017380046 date "2020-04-21" @default.
• W3017380046 modified "2023-10-02" @default.
• W3017380046 title "Urinary [TIMP-2] × [IGFBP7] and serum procalcitonin to predict and assess the risk for short-term outcomes in septic and non-septic critically ill patients" @default.
• W3017380046 cites W1972212260 @default.
• W3017380046 cites W1975477886 @default.
• W3017380046 cites W2026274122 @default.
• W3017380046 cites W2033462164 @default.
• W3017380046 cites W2040471946 @default.
• W3017380046 cites W2065737867 @default.
• W3017380046 cites W2072718771 @default.
• W3017380046 cites W2087720606 @default.
• W3017380046 cites W2102563147 @default.
• W3017380046 cites W2113394953 @default.
• W3017380046 cites W2123424949 @default.
• W3017380046 cites W2141559993 @default.
• W3017380046 cites W2148152947 @default.
• W3017380046 cites W2152354908 @default.
• W3017380046 cites W2158575236 @default.
• W3017380046 cites W2169504018 @default.
• W3017380046 cites W2240052930 @default.
• W3017380046 cites W2280404143 @default.
• W3017380046 cites W2282181907 @default.
• W3017380046 cites W2299296822 @default.
• W3017380046 cites W2461565061 @default.
• W3017380046 cites W2582602949 @default.
• W3017380046 cites W2591419591 @default.
• W3017380046 cites W2601941091 @default.
• W3017380046 cites W2764303225 @default.
• W3017380046 cites W2785137708 @default.
• W3017380046 cites W2793182734 @default.
• W3017380046 cites W2809779236 @default.
• W3017380046 cites W2885113440 @default.
• W3017380046 cites W2888749427 @default.
• W3017380046 cites W2896837151 @default.
• W3017380046 cites W2921824498 @default.
• W3017380046 cites W2963730652 @default.
• W3017380046 cites W4232355937 @default.
• W3017380046 cites W4385713768 @default.
• W3017380046 doi "https://doi.org/10.1186/s13613-020-00665-9" @default.
• W3017380046 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7174532" @default.
• W3017380046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32318859" @default.
• W3017380046 hasPublicationYear "2020" @default.
• W3017380046 type Work @default.
• W3017380046 sameAs 3017380046 @default.
• W3017380046 citedByCount "13" @default.
• W3017380046 countsByYear W30173800462021 @default.
• W3017380046 countsByYear W30173800462022 @default.
• W3017380046 countsByYear W30173800462023 @default.
• W3017380046 crossrefType "journal-article" @default.
• W3017380046 hasAuthorship W3017380046A5024171732 @default.
• W3017380046 hasAuthorship W3017380046A5040344241 @default.
• W3017380046 hasAuthorship W3017380046A5044009212 @default.
• W3017380046 hasAuthorship W3017380046A5044324138 @default.
• W3017380046 hasAuthorship W3017380046A5049227846 @default.
• W3017380046 hasAuthorship W3017380046A5049470840 @default.
• W3017380046 hasAuthorship W3017380046A5050853495 @default.
• W3017380046 hasAuthorship W3017380046A5053612775 @default.
• W3017380046 hasAuthorship W3017380046A5061657411 @default.
• W3017380046 hasAuthorship W3017380046A5066223278 @default.
• W3017380046 hasAuthorship W3017380046A5069947952 @default.
• W3017380046 hasAuthorship W3017380046A5076403607 @default.
• W3017380046 hasAuthorship W3017380046A5082770243 @default.
• W3017380046 hasAuthorship W3017380046A5088519816 @default.
• W3017380046 hasAuthorship W3017380046A5088632570 @default.
• W3017380046 hasBestOaLocation W30173800461 @default.
• W3017380046 hasConcept C10936531 @default.
• W3017380046 hasConcept C126322002 @default.
• W3017380046 hasConcept C167135981 @default.
• W3017380046 hasConcept C177713679 @default.
• W3017380046 hasConcept C185592680 @default.
• W3017380046 hasConcept C2777628635 @default.
• W3017380046 hasConcept C2778384902 @default.
• W3017380046 hasConcept C2778653478 @default.
• W3017380046 hasConcept C2780472472 @default.
• W3017380046 hasConcept C2781197716 @default.
• W3017380046 hasConcept C55493867 @default.
• W3017380046 hasConcept C71924100 @default.
• W3017380046 hasConcept C77411442 @default.
• W3017380046 hasConceptScore W3017380046C10936531 @default.
• W3017380046 hasConceptScore W3017380046C126322002 @default.
• W3017380046 hasConceptScore W3017380046C167135981 @default.
• W3017380046 hasConceptScore W3017380046C177713679 @default.
• W3017380046 hasConceptScore W3017380046C185592680 @default.

• next